AAAAAA

   
Results: 1-8 |
Results: 8
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation
Authors: Porter, DL Luger, SM Duffy, KM Stadtmauer, EA Laport, G Schuster, SJ Orloff, G Tsai, D McDaid, K Kathakali, A Leonard, DGB Antin, JH
Citation: Dl. Porter et al., Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation, BIOL BLOOD, 7(4), 2001, pp. 230-238
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients
Authors: Tsai, DE Hardy, CL Tomaszewski, JE Kotloff, RM Oltoff, KM Somer, BG Schuster, SJ Porter, DL Montone, KT Stadtmauer, EA
Citation: De. Tsai et al., Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients, TRANSPLANT, 71(8), 2001, pp. 1076-1088
Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination
Authors: Stadtmauer, EA Tsai, DE Sickles, CJ Mick, R Luger, SM Porter, DL Mangan, PA Schuchter, LM Schuster, SJ Loh, EY Magee, DA Sachs, RA Wall, ME Moore, J Buzby, GP Zaleta, E Kamoun, M Silberstein, LE
Citation: Ea. Stadtmauer et al., Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination, MED ONCOL, 16(4), 1999, pp. 279-288
Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases
Authors: Garcia-Manero, G Schuster, SJ Patrick, H Martinez, J
Citation: G. Garcia-manero et al., Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases, AM J HEMAT, 60(2), 1999, pp. 130-135
Extramedullary myeloid cell tumor of the urinary bladder in a patient withmyelodysplastic syndrome
Authors: Hurford, MT Gujral, S Schuster, SJ Schwarting, R
Citation: Mt. Hurford et al., Extramedullary myeloid cell tumor of the urinary bladder in a patient withmyelodysplastic syndrome, PATH RES PR, 195(10), 1999, pp. 699-703
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
Authors: Tsai, DE Moore, HCF Hardy, CL Porter, DL Loh, EY Vaughn, DJ Luger, S Schuster, SJ Stadtmauer, EA
Citation: De. Tsai et al., Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation, BONE MAR TR, 24(5), 1999, pp. 521-526
Serum soluble transferrin receptor and the prediction of marrow aspirate iron results in a heterogeneous group of patients
Authors: Means, RT Allen, J Sears, DA Schuster, SJ
Citation: Rt. Means et al., Serum soluble transferrin receptor and the prediction of marrow aspirate iron results in a heterogeneous group of patients, CLIN LAB H, 21(3), 1999, pp. 161-167
Should autologous or allogeneic stem-cell therapy be a part of consolidation therapy for all cases of adult acute myelogenous leukemia? - Response
Authors: Garcia-Manero, G Schuster, SJ
Citation: G. Garcia-manero et Sj. Schuster, Should autologous or allogeneic stem-cell therapy be a part of consolidation therapy for all cases of adult acute myelogenous leukemia? - Response, SEMIN ONCOL, 26(1), 1999, pp. XVI-XVII
Risultati: 1-8 |